For roughly two decades, the standard medical advice leaned toward caution: hormone therapy after menopause might raise dementia risk, based largely on one major trial from the early 2000s. A new Stanford-led study, published August 12 in Neurology, looked at the actual autopsied brains of over 21,000 women and found the opposite association for one specific type of hormone therapy.
Women who had used estrogen-only hormone therapy had 39% lower odds of a dementia diagnosis during their lifetimes and 35% lower odds of showing the physical hallmarks of Alzheimer’s, the amyloid plaques and tau tangles that pathologists look for, at autopsy. Estrogen-only users also tended to perform better on memory testing and function more independently later in life.
Why “Estrogen-Only” Is the Detail That Matters
This is the distinction that gets lost when a study like this gets compressed into a headline. Estrogen-only therapy is generally prescribed to women who’ve had a hysterectomy, since estrogen alone can raise the risk of uterine cancer in women who still have a uterus. Most women going through menopause with an intact uterus are prescribed combined estrogen-progestin therapy instead, and this study’s findings were specifically about the estrogen-only group.
That matters because the earlier research linking hormone therapy to increased dementia risk, the Women’s Health Initiative Memory Study, largely involved the combined therapy, tested in older women who started treatment years after menopause had already begun. Timing and formulation, it turns out, may change the picture substantially, not just whether someone took hormones at all.
What This Study Can’t Tell You
This is an observational, retrospective study, looking back at women who used hormone therapy decades ago. It shows an association, not proof that estrogen therapy prevents dementia. The researchers were direct about that limit themselves, and about a second one: the women in this data started hormone therapy under practices and timing that don’t necessarily match how it’s prescribed today.
There’s also a selection question worth sitting with. Women who pursued estrogen-only hormone therapy decades ago may have differed from non-users in ways related to overall health, healthcare access, or other factors the study can only partly control for. None of that erases a genuinely striking result across a dataset this large, but it’s the reason no researcher involved is telling women to start hormone therapy specifically to ward off Alzheimer’s.
What this does add is a real data point for a conversation a lot of women are already having with their doctors around menopause, about symptom relief, quality of life, and now a piece of longer-term brain health evidence that looks more encouraging than the fear that’s shaped hormone therapy decisions for twenty years.
What do you think? Should findings like this change how doctors talk to patients about hormone therapy, or is it still too early given the limits of the data? Let us know your thoughts in the comments on BeezLoop.com!
